BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9413942)

  • 21. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
    Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
    J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
    Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
    Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
    Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G
    J Immunol; 1999 Feb; 162(3):1739-48. PubMed ID: 9973437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development.
    Chen YT; Stockert E; Tsang S; Coplan KA; Old LJ
    Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8125-9. PubMed ID: 7667256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group.
    Palmieri G; Strazzullo M; Ascierto PA; Satriano SM; Daponte A; Castello G
    J Clin Oncol; 1999 Jan; 17(1):304-11. PubMed ID: 10458247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR.
    de Vries TJ; Fourkour A; Punt CJ; van de Locht LT; Wobbes T; van den Bosch S; de Rooij MJ; Mensink EJ; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 May; 80(5-6):883-91. PubMed ID: 10360670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA.
    Sundram U; Harvell JD; Rouse RV; Natkunam Y
    Mod Pathol; 2003 Aug; 16(8):802-10. PubMed ID: 12920225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
    Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
    Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune selection after antigen-specific immunotherapy of melanoma.
    Riker A; Cormier J; Panelli M; Kammula U; Wang E; Abati A; Fetsch P; Lee KH; Steinberg S; Rosenberg S; Marincola F
    Surgery; 1999 Aug; 126(2):112-20. PubMed ID: 10455872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
    de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
    J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression cloning of the cDNA encoding a melanoma-associated Ag recognized by mAb HMB-45. Identification as melanocyte-specific Pmel 17 cDNA.
    Wagner SN; Wagner C; Höfler H; Atkinson MJ; Goos M
    Lab Invest; 1995 Aug; 73(2):229-35. PubMed ID: 7637323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma.
    Linette GP; Shankara S; Longerich S; Yang S; Doll R; Nicolette C; Preffer FI; Roberts BL; Haluska FG
    J Immunol; 2000 Mar; 164(6):3402-12. PubMed ID: 10706736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
    Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
    Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
    von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
    J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative real-time RT-PCR in sentinel lymph nodes from melanoma patients. Detection of melanocytic mRNA predicts disease-free survival.
    Riber-Hansen R; Abrahamsen HN; Sorensen BS; Hamilton-Dutoit SJ; Steiniche T
    APMIS; 2008 Mar; 116(3):199-205. PubMed ID: 18377585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method.
    Arenberger P; Arenbergerova M; Gkalpakiotis S; Lippert J; Stribrna J; Kremen J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):56-64. PubMed ID: 18181974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
    Kawakami Y; Eliyahu S; Delgado CH; Robbins PF; Sakaguchi K; Appella E; Yannelli JR; Adema GJ; Miki T; Rosenberg SA
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6458-62. PubMed ID: 8022805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter.
    Kurnick JT; Ramirez-Montagut T; Boyle LA; Andrews DM; Pandolfi F; Durda PJ; Butera D; Dunn IS; Benson EM; Gobin SJ; van den Elsen PJ
    J Immunol; 2001 Aug; 167(3):1204-11. PubMed ID: 11466335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate.
    Davids V; Kidson SH; Hanekom GS
    Mol Pathol; 2003 Feb; 56(1):43-51. PubMed ID: 12560463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.